BACKGROUND: Neonates and young children require efficacious magnetic resonance imaging (MRI) examinations but are potentially more susceptible to the short- and long-term adverse effects of gadolinium-based contrast agents due to the immaturity of their body functions. OBJECTIVE: To evaluate the acute safety and diagnostic efficacy of gadoteridol (ProHance) for contrast-enhanced MRI of the central nervous system (CNS) in children ≤2 years of age. MATERIALS AND METHODS: One hundred twenty-five children ≤2 years old (including 57 children <6 months old) who underwent contrast-enhanced MRI of the CNS with gadoteridol at 0.1 mmol/kg body weight were retrospectively enrolled at five imaging centers. Safety data were assessed for acute/subacute adverse events in the 48 h following gadoteridol administration and, when available, vital signs, electrocardiogram (ECG) and clinical laboratory values obtained from blood samples taken from 48 h before until 48 h following the MRI exam. The efficacy of gadoteridol-enhanced MRI compared to unenhanced MRI for disease diagnosis was evaluated prospectively by three blinded, unaffiliated readers. RESULTS: Thirteen changes of laboratory values (11 mild, 1 moderate, 1 unspecified) were reported as adverse events in 7 (5.6%) patients. A relationship to gadoteridol was deemed possible though doubtful for two of these adverse events in two patients (1.6%). There were no clinical adverse events, no serious adverse events and no clinically meaningful changes in vital signs or ECG recordings. Accurate differentiation of tumor from non-neoplastic disease, and exact matching of specific MRI-determined diagnoses with on-site final diagnoses, was achieved in significantly more patients by each reader following the evaluation of combined pre- and post-contrast images compared to pre-contrast images alone (84.6-88.0% vs. 70.9-76.9%; P≤0.006 and 67.5-79.5% vs. 47.0-66.7%; P≤0.011, respectively). CONCLUSION: Gadoteridol at 0.1 mmol/kg body weight is safe, well tolerated and effective for contrast-enhanced MRI of the CNS in children ≤2 years of age.

Bambino Gesù Children's Hospital Rome Italy

C S Mott Children's Hospital University of Michigan Ann Arbor MI USA

Davis Medical Center University of California Sacramento CA USA

Department of Radiology Na Homolce Hospital Prague Czech Republic

Duke University School of Medicine Durham NC USA

Insitute of Radiology Radiodiagnostica e Neuroradiologia Fondazione Policlinico Universitario A Gemelli Universita Cattolica del Sacro Cuore Rome Italy

Johns Hopkins University School of Medicine Baltimore MD USA

Medical University of South Carolina Charleston SC USA

Pediatric Radiology Wolfson Children's Hospital Nemours Children's Health System 800 Prudential Drive Jacksonville FL 32207 USA

Zobrazit více v PubMed

Welk B, McArthur E, Morrow SA, et al. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA. 2016;316:96–98. doi: 10.1001/jama.2016.8096. PubMed DOI

Ackermans N, Taylor C, Tam R, et al. Effect of different doses of gadolinium contrast agent on clinical outcomes in MS. Mult Scler J Exp Transl Clin. 2019;5:2055217318823796. PubMed PMC

Cocozza S, Pontillo G, Lanzillo R, et al. MRI features suggestive of gadolinium retention do not correlate with expanded disability status scale worsening in multiple sclerosis. Neuroradiology. 2019;61:155–162. doi: 10.1007/s00234-018-02150-4. PubMed DOI

Vymazal J, Krámská L, Brožová H, et al. Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations. J Magn Reson Imaging. 2020;51:1912–1913. doi: 10.1002/jmri.26948. PubMed DOI PMC

Mithal LB, Patel PS, Mithal D, et al. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Pediatr Radiol. 2017;47:657–664. doi: 10.1007/s00247-017-3810-4. PubMed DOI

Blumfield E, Moore MM, Drake MK, et al. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a quality and safety committee report. Pediatr Radiol. 2017;47:665–673. doi: 10.1007/s00247-017-3807-z. PubMed DOI

European Medicines Agency (2017) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://www.ema.europa.eu/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en.pdf. Accessed 9 July 2020

Bracco Diagnostics Inc. (n.d.) ProHance prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020131s035lbl.pdf.

Shen Y, Goerner FL, Snyder C et al (2015) T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Investig Radiol 50:330–338 PubMed

Maravilla KR, Smith MP, Vymazal J, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study) AJNR Am J Neuroradiol. 2015;36:14–23. doi: 10.3174/ajnr.A4154. PubMed DOI PMC

Cho SB, Lee A-L, Chang HW, et al. Prospective multicenter study of the safety of gadoteridol in 6,163 patients. J Magn Reson Imaging. 2020;51:861–868. doi: 10.1002/jmri.26940. PubMed DOI PMC

McDonald RJ, McDonald JS, Dai D, et al. Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology. 2017;285:536–545. doi: 10.1148/radiol.2017161594. PubMed DOI

Jost G, Frenzel T, Boyken J, et al. Long-term excretion of gadolinium-based contrast agents: linear versus macrocyclic agents in an experimental rat model. Radiology. 2019;290:340–348. doi: 10.1148/radiol.2018180135. PubMed DOI

Bussi S, Coppo A, Botteron C, et al. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging. 2018;47:746–752. doi: 10.1002/jmri.25822. PubMed DOI PMC

Bussi S, Coppo A, Celeste R, et al. Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. Insights Imaging. 2020;11:11–20. doi: 10.1186/s13244-019-0824-5. PubMed DOI PMC

Enterline DS, Martin KW, Parmar HA, et al. Safety and diagnostic efficacy of gadobenate dimeglumine in MRI of the brain and spine of neonates and infants. AJNR Am J Neuroradiol. 2019;40:2001–2009. PubMed PMC

Kunze C, Mentzel H-J, Krishnamurthy R, et al. Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Investig Radiol. 2016;51:50–57. doi: 10.1097/RLI.0000000000000204. PubMed DOI

Elster AD, Moody DM, Ball MR, Laster DW. Is Gd-DTPA required for routine cranial MR imaging? Radiology. 1989;173:231–238. doi: 10.1148/radiology.173.1.2781014. PubMed DOI

McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276–282. doi: 10.11613/BM.2012.031. PubMed DOI PMC

Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am. 1987;34:571–590. doi: 10.1016/S0031-3955(16)36251-4. PubMed DOI

Andropoulos DB. Appendix B: pediatric normal laboratory values. In: Gregory GA, Andropoulos DB, editors. Gregory’s pediatric anesthesia. 5. Hoboken: Blackwell Publishing Ltd.; 2011. pp. 1300–1315.

Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 41:959–998 PubMed

Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53–72. doi: 10.3390/pharmaceutics3010053. PubMed DOI PMC

Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66:185–200. doi: 10.1093/toxsci/66.2.185. PubMed DOI

Scala M, Koob M, de Buttet S, et al. A pharmacokinetics, efficacy, and safety study of gadoterate meglumine in pediatric subjects aged younger than 2 years. Investig Radiol. 2018;53:70–79. doi: 10.1097/RLI.0000000000000412. PubMed DOI PMC

Bhargava R, Noga M. Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years — a single-center, observational study. Magn Reson Insights. 2013;6:1–12. PubMed PMC

Emond S, Brunelle F. Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol. 2011;41:1401–1406. doi: 10.1007/s00247-011-2167-3. PubMed DOI

Farmakis SG, Hardy AK, Mahmoud SY, et al. Safety of gadoterate meglumine in children younger than 2 years of age. Pediatr Radiol. 2020;50:855–862. doi: 10.1007/s00247-020-04626-z. PubMed DOI

Bayer HealthCare Pharmaceuticals (2011) Gadavist prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf. Accessed 15 Jan 2021

Stanescu AL, Shaw DW, Murata N, et al. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol. 2020;50:388–396. doi: 10.1007/s00247-019-04535-w. PubMed DOI

Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents — review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. Pediatr Radiol. 2019;49:448–457. doi: 10.1007/s00247-018-4304-8. PubMed DOI

Robert P, Violas X, Grand S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Investig Radiol. 2016;51:73–82. doi: 10.1097/RLI.0000000000000241. PubMed DOI PMC

Lohrke J, Frisk A-L, Frenzel T, et al. Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Investig Radiol. 2017;52:324–333. doi: 10.1097/RLI.0000000000000344. PubMed DOI PMC

Aime S. Differences in molecular structure markedly affect GBCA elimination behavior. Radiology. 2019;291:267–268. doi: 10.1148/radiol.2019182748. PubMed DOI

Guidolin N, Travagin F, Giovenzana GB, et al. Interaction of macrocyclic gadolinium-based MR contrast agents with type I collagen. Equilibrium and kinetic studies. Dalton Trans. 2020;49:14863–14870. doi: 10.1039/D0DT03314F. PubMed DOI

Sengupta P. The laboratory rat: relating its age with human's. Int J Prev Med. 2013;4:624–630. PubMed PMC

Young JR, Pope WB, Bobinski M. Gadolinium deposition within the pediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of 4 doses of the macrocyclic agent gadoteridol. AJNR Am J Neuroradiol. 2018;39:1604–1608. doi: 10.3174/ajnr.A5748. PubMed DOI PMC

Rossi Espagnet MC, Bernardi B, Pasquini L, et al. Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol. 2017;47:1345–1352. doi: 10.1007/s00247-017-3874-1. PubMed DOI

Topcuoglu ED, Topcuoglu OM, Semiz Oysu A, Bukte Y. Does gadoterate meglumine cause gadolinium retention in the brain of children? A case-control study. J Magn Reson Imaging. 2020;51:1471–1477. doi: 10.1002/jmri.26954. PubMed DOI